A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, Recentin), in Patients With Advanced Solid Tumours.

Trial Profile

A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, Recentin), in Patients With Advanced Solid Tumours.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Cediranib (Primary) ; Rifampicin
  • Indications Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Jan 2018 Planned End Date changed from 29 Dec 2017 to 31 Dec 2018.
    • 18 Sep 2017 Planned End Date changed from 3 Dec 2016 to 29 Dec 2017.
    • 22 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top